192 related articles for article (PubMed ID: 29896310)
1. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes.
Hsieh YC; Wang HE; Lin WW; Roffler SR; Cheng TC; Su YC; Li JJ; Chen CC; Huang CH; Chen BM; Wang JY; Cheng TL; Chen FM
Theranostics; 2018; 8(11):3164-3175. PubMed ID: 29896310
[No Abstract] [Full Text] [Related]
2. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
3. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
[TBL] [Abstract][Full Text] [Related]
4. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG.
McSweeney MD; Price LSL; Wessler T; Ciociola EC; Herity LB; Piscitelli JA; DeWalle AC; Harris TN; Chan AKP; Saw RS; Hu P; Jennette JC; Forest MG; Cao Y; Montgomery SA; Zamboni WC; Lai SK
J Control Release; 2019 Oct; 311-312():138-146. PubMed ID: 31454530
[TBL] [Abstract][Full Text] [Related]
5. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
[TBL] [Abstract][Full Text] [Related]
6. Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[
Wu CY; Tang JH; Chan PC; Li JJ; Lin MH; Shen CC; Liu RS; Wang HE
Mol Imaging Biol; 2017 Jun; 19(3):408-420. PubMed ID: 27730471
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
8. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T
Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114
[TBL] [Abstract][Full Text] [Related]
9. Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies.
Tung HY; Su YC; Chen BM; Burnouf PA; Huang WC; Chuang KH; Yan YT; Cheng TL; Roffler SR
Mol Cancer Ther; 2015 Jun; 14(6):1317-26. PubMed ID: 25852063
[TBL] [Abstract][Full Text] [Related]
10. Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy.
Chuang KH; Wang HE; Chen FM; Tzou SC; Cheng CM; Chang YC; Tseng WL; Shiea J; Lin SR; Wang JY; Chen BM; Roffler SR; Cheng TL
Mol Cancer Ther; 2010 Jun; 9(6):1903-12. PubMed ID: 20501805
[TBL] [Abstract][Full Text] [Related]
11. Measurement of poly(ethylene glycol) by cell-based anti-poly(ethylene glycol) ELISA.
Chuang KH; Tzou SC; Cheng TC; Kao CH; Tseng WL; Shiea J; Liao KW; Wang YM; Chang YC; Huang BJ; Wu CJ; Chu PY; Roffler SR; Cheng TL
Anal Chem; 2010 Mar; 82(6):2355-62. PubMed ID: 20178318
[TBL] [Abstract][Full Text] [Related]
12. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
13. Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer.
Kojima C; Yao J; Nakajima K; Suzuki M; Tsujimoto A; Kuge Y; Ogawa M; Matsumoto A
Int J Pharm; 2024 Jun; 659():124193. PubMed ID: 38703934
[TBL] [Abstract][Full Text] [Related]
14. Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies.
Freire Haddad H; Burke JA; Scott EA; Ameer GA
Regen Eng Transl Med; 2022; 8(1):32-42. PubMed ID: 33786367
[TBL] [Abstract][Full Text] [Related]
15. Enhancement Effect of a Variable Topology of a Membrane-Tethered Anti-Poly(ethylene glycol) Antibody on the Sensitivity for Quantifying PEG and PEGylated Molecules.
Lin WW; Cheng YA; Kao CH; Roffler SR; Lee YC; Chen BM; Hsieh YC; Chen IJ; Huang BC; Wang YT; Tung YC; Huang MY; Chen FM; Cheng TL
Anal Chem; 2017 Jun; 89(11):6082-6090. PubMed ID: 28485140
[TBL] [Abstract][Full Text] [Related]
16. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity.
Charrois GJ; Allen TM
J Pharmacol Exp Ther; 2003 Sep; 306(3):1058-67. PubMed ID: 12808004
[TBL] [Abstract][Full Text] [Related]
17. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
18. Revealing Dynamics of Accumulation of Systemically Injected Liposomes in the Skin by Intravital Microscopy.
Griffin JI; Wang G; Smith WJ; Vu VP; Scheinman R; Stitch D; Moldovan R; Moghimi SM; Simberg D
ACS Nano; 2017 Nov; 11(11):11584-11593. PubMed ID: 29045127
[TBL] [Abstract][Full Text] [Related]
19. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
20. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
